Copy
Newsletter May 22, 2020
 

Jeff Robinson, CEO of Wuhan, Provides Key Updates and Outlook in a New Audio Interview with SmallCapVoice.com
 

Austin, TX  5/22/20 -- SmallCapVoice.com, Inc. (SCV) and Wuhan General Group, Inc. (OTC PINK: WUHN) (the "Company" and "Wuhan"), announced today that a new audio interview with the Company is now available.
 
The interview featuring an overview of WUHN’s current news and moves can be heard at interview-with-wuhan-general-group-inc-ceo
 
Jeff Robinson, CEO of Wuhan, called into SmallCapvoice.com to go over the business model and markets that his company operates in. Wuhan is currently positioning itself to become a major player in the estimated 146.4 billion dollars medical cannabidiol (CBD) space, as well as the promising psilocybin medical health sector.

The Company’s subsidiary MJ MedTech is a cosmetics and food for special medical purposes (FSMP) company with leading alternative plant-based cannabinoids and psilocybin medical research, formulation and delivery system divisions. Cannabinoids and mushroom-based formulations are under the Dr. AnnaRxTM and MedspressoTM brands.

The Company’s cannabinoids research and development division are focused on new treatments to help patients who suffer from chronic and inflammatory diseases: inflammatory bowel syndrome, arthritis, chronic respiratory diseases, migraine, sleep disorders, cancer and diabetes.

In addition, its division M2Bio is researching and developing indications for psilocybin new therapies that will help patients diagnosed with mental health disorders, Alzheimer’s, Parkinson’s, major depressive disorder, drug and alcohol addiction, and cardiovascular diseases.

As well, Wuhan has been researching multiple medicinal mushroom types in order to formulate its upcoming range of mushroom-infused cosmetics, coffee, and teas for commercialization in late 2020 within its Dr. AnnaRxTM and MedspressoTM brands.

In the interview Robinson stated, “We are one of only a handful of companies in the world working with psilocybin and conducting clinical trials. On the CBD side, once the lockdown ends in South Africa, our products will be on store shelves. That would be the products in the Dr. AnnaRxTM and MedspressoTM brands. These are really exciting times for our company. We are thankful for the opportunity to share our story with our shareholders and the SmallCapVoice.com listening audience.
 
“The company name change, updated financials and fully reporting status, key employee new hires, strategic new partnerships, research findings and new clinical initiatives - just a few items soon to be shared. We are extremely excited!”
 
Wuhan General Group, Inc. is a client of Stockvest. StockVest's team of top Influencers introduces publicly traded companies to a wide audience of investors from around the globe helping public companies attain maximum market awareness resulting in increased trading volume, a broadened shareholder base and increased share valuations.
 
 
About Wuhan General Group, Inc.
 
Wuhan General Group, Inc. through its wholly-owned subsidiary  MJ  MedTech is a  cosmetics and food for special medical purposes  (FSMP)  company with leading alternative plant-based cannabinoids and psilocybin medical research,  formulation and delivery system divisions. Cannabinoids and mushroom-based formulations are under the Dr. AnnaRxTM and MedspressoTM brands. In addition, its established division, M2Bio is researching and developing indications for psilocybin new therapies that will help patients diagnosed with mental health disorders, Alzheimer’s, Parkinson’s, major depressive disorder, drug and alcohol addiction, cardiovascular diseases and PTSD. Our mission is to advance botanical-based medicine to the forefront by deploying best-practice science and medicine, clinical research and emerging technologies. Wuhan is listed and traded on the Over the Counter Bulletin Board of NASDAQ under the trading symbol “WUHN”.
 
Wuhan General Group, Inc.
 
Publicly traded company (OTC Pink: WUHN)
 
Website: www.wuhn.org
 
About SmallCapVoice.com

SmallCapVoice.com, Inc. is a recognized corporate investor relations firm, with clients nationwide, known for its ability to help emerging growth companies, small-cap and micro-cap stocks build a following among retail and institutional investors. SmallCapVoice.com utilizes its stock newsletter to feature its daily stock picks, podcasts, as well as its clients' financial news releases. SmallCapVoice.com also offers individual investors all the tools they need to make informed decisions about the stocks in which they are interested. Tools like stock charts, stock alerts, and Company Information Sheets can assist with investing in stocks that are traded on the OTCMarkets.

To learn more about SmallCapVoice.com and its services, please visit https://www.smallcapvoice.com/small-cap-stock-otc-investor-relations-financial-public-relations/.

Socialize with SmallCapVoice and their clients at:
Facebook: https://www.facebook.com/SmallCapVoice/  
Twitter: https://twitter.com/smallcapvoice   
Instagram: https://www.instagram.com/smallcapvoice/

Forward-Looking Statements

Safe Harbour Statement - In addition to historical information, this press release may contain statements that constitute forward-looking statements within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Forward-looking statements contained in this press release include the intent, belief, or expectations of the Company and members of its management team with respect to the Company's future business operations and the assumptions upon which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties and that actual results may differ materially from those contemplated by such forward-looking statements. Factors that could cause these differences to include, but are not limited to, failure to complete anticipated sales under negotiations, lack of revenue growth, client discontinuances, failure to realize improvements in performance, efficiency and profitability, and adverse developments with respect to litigation or increased litigation costs, the operation or performance of the Company's business units or the market price of its common stock. Additional factors that could cause actual results to differ materially from those contemplated within this press release can also be found on the Company's website. The Company disclaims any responsibility to update any forward-looking statements.

For further information contact:

Public Relations
E-mail: info@wuhn.org

For SmallCapVoice.com:
Stuart T. Smith
512-267-2430
info@smallcapvoice.com
Source: SmallCapVoice.com

 
Twitter Twitter
LinkedIn LinkedIn
Facebook Facebook
 
 

                     Wuhan General Group, Inc.  |  6500 Transcanada Hwy 400   |  Quebec, Canada H9R0A5

 

Copyright © 2020 Wuhan General Group or its affiliates. All rights reserved. Medspresso, the logo, and all other related logos are trademarks of Wuhan General Group Inc or its affiliates.

You've received this email because  you opted in via our website or have shown an interest in the past. If you wish to change how you receive these emails?
You can update your preferences or unsubscribe from this list.

 

Email Marketing Powered by Mailchimp